vs
ABEONA THERAPEUTICS INC.（ABEO）与AC Immune SA（ACIU）财务数据对比。点击上方公司名可切换其他公司
Abeona Therapeutics是一家临床阶段生物制药公司，专注于研发针对致命罕见遗传病的创新基因与细胞疗法，其管线覆盖多种未被满足的临床需求，主要为北美、欧洲地区缺乏有效治疗方案的患者群体服务。
AC Immune SA是一家临床阶段生物制药企业，专注于开发阿尔茨海默病、帕金森病及罕见tau蛋白病等神经退行性疾病的创新疗法与诊断方案，与全球领先药企展开合作，致力于满足神经疾病领域未被满足的临床需求。
ABEO vs ACIU — 直观对比
营收规模更大
ACIU
是对方的Infinity倍
$0
损益表 — Q3 2025 vs Q2 2025
| 指标 | | |
|---|---|---|
| 营收 | $0 | $1.4M |
| 净利润 | $-5.2M | $-23.3M |
| 毛利率 | — | — |
| 营业利润率 | — | -1484.5% |
| 净利率 | — | -1622.4% |
| 营收同比 | — | 90.1% |
| 净利润同比 | 82.9% | 6.9% |
| 每股收益（稀释后） | $-0.10 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABEOACIU
| Q3 25 | $0 | — | ||
| Q2 25 | $400.0K | $1.4M | ||
| Q2 24 | — | $755.7K | ||
| Q3 22 | — | $4.3M |
净利润ABEOACIU
| Q3 25 | $-5.2M | — | ||
| Q2 25 | $108.8M | $-23.3M | ||
| Q2 24 | — | $-25.0M | ||
| Q3 22 | — | $-14.9M |
营业利润率ABEOACIU
| Q3 25 | — | — | ||
| Q2 25 | -5698.0% | -1484.5% | ||
| Q2 24 | — | -3051.1% | ||
| Q3 22 | — | -342.2% |
净利率ABEOACIU
| Q3 25 | — | — | ||
| Q2 25 | 27208.3% | -1622.4% | ||
| Q2 24 | — | -3313.0% | ||
| Q3 22 | — | -343.6% |
每股收益（稀释后）ABEOACIU
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $1.71 | — | ||
| Q2 24 | — | — | ||
| Q3 22 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $207.1M | $28.3M |
| 总债务越低越好 | $19.8M | — |
| 股东权益账面价值 | $171.2M | $82.2M |
| 总资产 | $231.1M | $209.2M |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资ABEOACIU
| Q3 25 | $207.1M | — | ||
| Q2 25 | $225.5M | $28.3M | ||
| Q2 24 | — | $56.7M | ||
| Q3 22 | — | $49.0M |
总债务ABEOACIU
| Q3 25 | $19.8M | — | ||
| Q2 25 | $19.6M | — | ||
| Q2 24 | — | — | ||
| Q3 22 | — | — |
股东权益ABEOACIU
| Q3 25 | $171.2M | — | ||
| Q2 25 | $163.6M | $82.2M | ||
| Q2 24 | — | $135.8M | ||
| Q3 22 | — | $209.1M |
总资产ABEOACIU
| Q3 25 | $231.1M | — | ||
| Q2 25 | $246.2M | $209.2M | ||
| Q2 24 | — | $261.3M | ||
| Q3 22 | — | $226.1M |
负债/权益比ABEOACIU
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q2 24 | — | — | ||
| Q3 22 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-21.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-23.7M | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ABEOACIU
| Q3 25 | $-21.2M | — | ||
| Q2 25 | $-18.8M | — | ||
| Q2 24 | — | — | ||
| Q3 22 | — | — |
自由现金流ABEOACIU
| Q3 25 | $-23.7M | — | ||
| Q2 25 | $-21.7M | — | ||
| Q2 24 | — | — | ||
| Q3 22 | — | — |
自由现金流率ABEOACIU
| Q3 25 | — | — | ||
| Q2 25 | -5421.3% | — | ||
| Q2 24 | — | — | ||
| Q3 22 | — | — |
资本支出强度ABEOACIU
| Q3 25 | — | — | ||
| Q2 25 | 725.3% | — | ||
| Q2 24 | — | — | ||
| Q3 22 | — | — |
现金转化率ABEOACIU
| Q3 25 | — | — | ||
| Q2 25 | -0.17× | — | ||
| Q2 24 | — | — | ||
| Q3 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
